What Is Melatonin

Melatonin is a hormone synthesized primarily by the pineal gland during darkness, serving as the body's internal signal that night has arrived. Beyond timing sleep, it functions as a direct antioxidant capable of neutralizing reactive oxygen and nitrogen species within cells. Available as an over-the-counter supplement in many countries, it is one of the most widely used compounds for sleep support.

Sleep quality is one of the strongest predictors of long-term health outcomes, and melatonin sits at the center of the biological machinery that initiates and maintains sleep. As pineal melatonin output declines with age, the downstream consequences extend beyond restless nights: reduced antioxidant defense in the brain, impaired immune surveillance during sleep, and disrupted metabolic rhythms that depend on a robust circadian signal. These overlapping vulnerabilities make the age-related drop in melatonin a point of interest for longevity research.

Melatonin's relevance also extends to its role as a mitochondrial protectant. Unlike most antioxidants, melatonin accumulates inside mitochondria at concentrations far higher than in plasma. Because mitochondrial dysfunction is implicated in nearly every hallmark of aging, from cellular senescence to chronic inflammation, maintaining adequate melatonin levels may support the organelles most susceptible to oxidative damage over a lifetime. Whether this protective effect translates into measurable lifespan or healthspan extension in humans remains an open question, but the biological rationale is grounded in well-characterized physiology.

Melatonin synthesis begins when light levels fall. Photoreceptors in the retina relay darkness signals to the suprachiasmatic nucleus (SCN), the brain's master circadian clock, which then disinhibits the pineal gland via a multi-synaptic pathway running through the superior cervical ganglion. The pineal converts serotonin to melatonin through two enzymatic steps: serotonin is first acetylated by arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme, and then methylated by hydroxyindole-O-methyltransferase (HIOMT). The resulting melatonin is released into the bloodstream and cerebrospinal fluid, reaching peak concentrations in the middle of the night.

At its target tissues, melatonin activates two G-protein-coupled receptors. MT1 receptors promote sleepiness by inhibiting SCN neuronal firing, while MT2 receptors help shift the phase of the circadian clock, making them relevant for jet lag and shift work. These receptor-mediated actions coordinate a cascade of downstream events: core body temperature drops, cortisol secretion is suppressed, and growth hormone release during early sleep is facilitated. The combined effect is not merely sedation but the orchestration of a physiological state optimized for tissue repair and memory consolidation.

Independent of its receptor signaling, melatonin acts as an electron donor that directly neutralizes hydroxyl radicals, peroxyl radicals, and peroxynitrite. Its metabolites (cyclic 3-hydroxymelatonin, AFMK, and AMK) are themselves antioxidants, creating a scavenging cascade in which a single melatonin molecule can detoxify multiple reactive species. Melatonin also upregulates endogenous antioxidant enzymes such as glutathione peroxidase and superoxide dismutase through gene expression effects. This dual action, both direct scavenging and enzymatic upregulation, makes its antioxidant profile distinct from compounds like vitamin C that rely on a single mechanism.

Melatonin supplements are available in immediate-release tablets, extended-release (sustained-release) tablets, sublingual lozenges, liquid drops, gummies, and topical creams. Immediate-release formulations produce a rapid spike in blood melatonin that mimics the natural onset curve, making them suitable for people whose primary issue is falling asleep. Extended-release formulations attempt to replicate the sustained plateau of endogenous melatonin across the night; these may be more relevant for individuals who fall asleep normally but wake frequently in the second half of the night.

Sublingual delivery bypasses first-pass liver metabolism, potentially producing faster onset and higher bioavailability per milligram compared to swallowed tablets. Liquid forms allow precise micro-dosing, which is useful for people who want to start below 0.5 mg. Gummies are popular but often contain added sugars and may deliver less precise dosing. Some compounding pharmacies offer melatonin in transdermal or intranasal formats, though clinical data on these delivery routes remain limited.

The physiological nighttime rise in melatonin produces blood levels equivalent to roughly 0.1 to 0.3 mg of an oral dose. Most commercial supplements contain 1 to 10 mg, which pushes plasma concentrations far beyond the natural range. Research comparing doses from 0.3 mg to 5 mg has found that lower, physiological doses often produce equivalent or superior sleep outcomes compared to supraphysiological amounts, with fewer side effects. The key reason is that melatonin receptors can become desensitized at chronically elevated ligand concentrations.

Timing is at least as important as dose. For standard sleep-onset support, taking melatonin 30 to 60 minutes before the desired bedtime aligns the exogenous peak with the natural dimming of alertness. For circadian phase advancement (as in delayed sleep phase syndrome), taking a small dose 3 to 5 hours before habitual sleep onset can shift the clock earlier over successive days. Individuals over 65 may benefit from slightly higher doses (1 to 2 mg) because age-related decline in first-pass metabolism can reduce effective bioavailability, but this remains an area of active study.

Independent testing of melatonin supplements has repeatedly found significant discrepancies between labeled and actual melatonin content. One widely cited analysis of commercial products found that actual melatonin content ranged from 83% below to over 400% above what was stated on the label. Some products also contained serotonin as an undeclared contaminant. These inconsistencies make brand selection consequential.

Look for products that carry third-party certification from organizations such as USP, NSF International, or ConsumerLab, which verify that the product contains what it claims in the amount stated, without harmful contaminants. Pharmaceutical-grade melatonin, available in some countries by prescription, undergoes more stringent manufacturing controls than dietary supplement-grade products. Choosing products with minimal excipients, no unnecessary fillers, and clear lot-specific testing documentation provides an additional layer of quality assurance.

Clinical evidence for melatonin's sleep-onset effects is well established. Multiple meta-analyses of randomized controlled trials have found that exogenous melatonin reduces sleep latency by a modest but statistically significant amount and may slightly increase total sleep time, particularly in individuals with delayed sleep phase disorder or jet lag. Effect sizes for general insomnia tend to be smaller, and melatonin does not appear to produce the magnitude of sedation seen with pharmaceutical hypnotics. Its safety profile in these trials is consistently favorable, with side effects rarely exceeding placebo rates at doses below 5 mg.

The antioxidant and longevity-related research is more preliminary. Animal studies, primarily in rodents, have shown that chronic melatonin supplementation can extend lifespan in some strains, reduce markers of oxidative damage, and delay age-related decline in immune function. However, these findings have not been replicated in controlled human longevity trials, which would require decades of follow-up. Observational data suggesting that shift workers (who have chronically suppressed melatonin) experience higher rates of cancer, metabolic disease, and cardiovascular events are consistent with melatonin's protective role but cannot isolate melatonin from the many other health consequences of disrupted sleep. Human trials exploring melatonin as an adjunct in oncology, neurodegeneration, and metabolic syndrome are ongoing but have not yet produced definitive conclusions.

Melatonin is generally well tolerated in adults at doses up to 5 mg, with the most commonly reported side effects being morning drowsiness, headache, dizziness, and unusually vivid dreams. Higher doses (10 mg and above) appear more likely to cause next-day sedation and may paradoxically worsen sleep quality in some individuals. Melatonin can interact with blood thinners, immunosuppressants, diabetes medications, and blood pressure drugs. Its use in children, pregnant or nursing individuals, and people with autoimmune conditions warrants careful individual evaluation. Because melatonin is classified as a dietary supplement in the United States rather than a pharmaceutical, product quality and actual dose accuracy can vary substantially between brands.